Long-Term Clinical Outcomes of 0.015% Tacrolimus HPβCD Eye Drops in Ocular Surface Inflammatory Disorders

Key Points

• To evaluate the long-term efficacy and safety of 0.015% tacrolimus/HPβCD eye drops in treating ocular surface inflammatory disorders.
• Conducted over 12 months
• Included diverse ocular inflammatory conditions
• Analyzed patient-reported outcomes
• Monitored for corticosteroid dependency
• Demonstrated sustained clinical stability
• Reported significant patient-reported benefits
• Reduced reliance on steroid treatments